New dates for two FDA diabetes panels

FDA's Endocrinologic and Metabolic Drugs Advisory Committee rescheduled two meetings to discuss Type II diabetes treatments.

The committee will now meet May 24 to discuss an NDA from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for Xultophy insulin degludec/liraglutide. The therapy is a fixed dose-combination of Tresiba, a long-acting insulin analog, and Victoza, a long-acting glucagon-like peptide-1 (GLP-1) analog. The meeting was rescheduled from May 25 (see BioCentury Extra, March 16). ...